Columbus Circle Investors bought a new stake in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 57,876 shares of the biotechnology company’s stock, valued at approximately $3,671,000. Columbus Circle Investors owned 0.06% of Arrowhead Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently added to or reduced their stakes in ARWR. Municipal Employees Retirement System of Michigan grew its stake in Arrowhead Pharmaceuticals by 1.3% during the third quarter. Municipal Employees Retirement System of Michigan now owns 28,560 shares of the biotechnology company’s stock worth $805,000 after buying an additional 380 shares during the period. Nisa Investment Advisors LLC grew its stake in Arrowhead Pharmaceuticals by 96.2% during the third quarter. Nisa Investment Advisors LLC now owns 1,020 shares of the biotechnology company’s stock worth $29,000 after buying an additional 500 shares during the period. United Services Automobile Association grew its stake in Arrowhead Pharmaceuticals by 2.6% during the second quarter. United Services Automobile Association now owns 20,515 shares of the biotechnology company’s stock worth $544,000 after buying an additional 522 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Arrowhead Pharmaceuticals by 10.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,701 shares of the biotechnology company’s stock worth $161,000 after buying an additional 531 shares during the period. Finally, Comerica Bank grew its stake in Arrowhead Pharmaceuticals by 0.7% during the third quarter. Comerica Bank now owns 89,234 shares of the biotechnology company’s stock worth $3,291,000 after buying an additional 627 shares during the period. Hedge funds and other institutional investors own 70.33% of the company’s stock.
Several equities research analysts have issued reports on the stock. Piper Jaffray Companies boosted their price objective on shares of Arrowhead Pharmaceuticals from $72.00 to $80.00 and gave the stock an “overweight” rating in a research note on Monday, December 9th. BidaskClub downgraded shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 16th. Svb Leerink initiated coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 21st. They set an “underperform” rating and a $32.00 target price on the stock. ValuEngine cut shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, S&P Equity Research reissued a “buy” rating on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, November 26th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $61.14.
NASDAQ ARWR opened at $44.61 on Friday. The stock has a market cap of $4.42 billion, a P/E ratio of 64.65 and a beta of 1.97. The company’s fifty day simple moving average is $61.53 and its 200-day simple moving average is $42.34. Arrowhead Pharmaceuticals Inc has a 52 week low of $12.72 and a 52 week high of $73.72.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Monday, November 25th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by ($0.03). The company had revenue of $43.29 million during the quarter, compared to analyst estimates of $36.97 million. Arrowhead Pharmaceuticals had a net margin of 40.27% and a return on equity of 32.30%. On average, equities analysts forecast that Arrowhead Pharmaceuticals Inc will post -0.16 earnings per share for the current fiscal year.
In related news, General Counsel Patrick O’brien sold 14,625 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $60.12, for a total value of $879,255.00. Following the sale, the general counsel now directly owns 267,406 shares of the company’s stock, valued at $16,076,448.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Kenneth Allen Myszkowski sold 37,884 shares of the company’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $40.85, for a total transaction of $1,547,561.40. Following the completion of the sale, the chief financial officer now directly owns 351,420 shares in the company, valued at $14,355,507. The disclosure for this sale can be found here. Insiders sold 286,402 shares of company stock worth $17,138,919 over the last ninety days. 4.80% of the stock is currently owned by corporate insiders.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company’s pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Read More: Trading based on a resistance level
Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR).
Receive News & Ratings for Arrowhead Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
